THE ROLE OF MAGNETIC RESONANCE SPECTROSCOPY IN EVALUATION OF PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 | ||
| ALEXMED ePosters | ||
| Article 4, Volume 4, Issue 3, September 2022, Pages 35-36 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2022.163107.1469 | ||
| Authors | ||
| Reda Darweesh Mohamed Abdelrahman1; Ahmed Abogabal1; Amal Shawky Ismail2; Salma Elsayed Marie* 1 | ||
| 1Department of Radiodiagnosis and Intervention, Faculty of Medicine, University of Alexandria | ||
| 2Radiodiagnosis and Intervention, Medicine, Alexandria, Alexandria, Egypt | ||
| Abstract | ||
| Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder which predisposes patients to develop benign and malignant neoplasms, mostly due to a loss of function mutation in the neurofibromatosis type 1 (NF1) gene. NF1's protein product, neurofibromin, controls Ras pathway inactivation and so functions as a tumor suppressor. A decrease in neurofibromin, which is found in neurons, Schwann cells, and melanocytes, predisposes patients with NF1 to tumors in both the central and peripheral nervous systems. The most common focal brain lesions found in NF1 patients are hamartomas (FASI) and gliomas. Proton Magnetic resonance spectroscopy is one such technique which provides a noninvasive method for characterizing the cellular biochemistry which underlies brain pathologies, helping in differentiating between hamartomas (FASI) and gliomas in our study based on the spectroscopic analysis of different metabolites AIM OF THE WORK: This study aimed to assess the role of MR spectroscopy in differentiating between hamartomas (FASI) & gliomas in NF1 patients. And assessing the metabolite differences in the normal appearing brain of NF1 patients and normal healthy volunteers. | ||
| Keywords | ||
| Neurofibromatosis type 1 (NF1); MAGNETIC RESONANCE SPECTROSCOPY; hamartomas (FASI) and gliomas | ||
|
Supplementary Files
|
||
|
Statistics Article View: 139 |
||
